FDA Fast Tracks Investigational Treatment for Liver Fibrosis
The company recently presented preliminary results of ongoing Phase 1b/2 studies for ND-L02-s0201 at the The Liver Meeting 2015 in San Francisco, California.
AASLD 2015
Expensive Hepatitis C Medications Denied to Almost Half of Medicaid Patients
Most common reason for denial was “insufficient information to assess medical need.”
Investigational Medication Well Tolerated in Patients With HCV Who Inject Drugs
Findings are preliminary, but show potential for treating at-risk populations.
Liver Transplantation Outcomes Similar for Obese and Lower Weight Patients
Obese patients are just as likely to benefit from liver transplantation and in fact are more likely to die while waiting on transplant lists than patients with lower BMI.
Sofosbuvir-Velpatasvir Successful in Hepatitis C Treatment, Regardless of Genotype
Three studies show high sustained virologic response rates, regardless of HCV genotype.
- Loading...
Loading...
Next post in AASLD 2015
Loading... 
Loading...